The epidermal growth factor receptor (EGFR) is a long known, versatile signal transducer that has been well conserved during evolution. It functions in a wide range of cellular processes including cell fate determination, proliferation, cell migration and apoptosis. The activity of the EGFR is subject to modulation by multiple positive and negative regulators and is transduced to the nucleus by...

Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is licensed for the treatment of unselected recurrent non-small cell lung cancer (NSCLC) patients, however, it is being investigated in all stages of NSCLC. Erlotinib is well tolerated, with common toxicities...

This work shows the synthesis of a drug delivery system made casein nanoparticles able to host hydrophobic molecules and be functionalized with aptamers targeting epidermal growth factor receptor.

Phospholipase C-yl (PLC-yl) is a well characterized substrate for the epidermal growth factor receptor tyrosine kinase and has been implicated in the intracellular biochemical signaling cascade which occurs following stimulation of cells with epidermal growth factor. The in vivo localization of PLC-’yl was examined by immunohistochemistry in sections of normal human skin and in skin sections fr...

Management of patients with metastatic hormone receptor-positive breast cancer poses a challenge due to the inevitable development of endocrine resistance. Hormone resistance is associated with a complex interaction of the estrogen receptor with growth factors, transmembrane receptors, and intracellular growth cascades. The PI3K/Akt/mTOR pathway plays a major role in hormone resistance and prol...

OBJECTIVE Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with non-small cell lung cancer. Although the safety profile of these drugs is favorable, a small proportion of patients with EGFR mutation-positive non-small cell lung cance...